Debiopharm

This page shows the latest Debiopharm news and features for those working in and with pharma, biotech and healthcare.

Merck KGaA gains exclusive rights to Debiopharma’s late-stage oncology asset

Development and commercialisation deal could be worth up to $1.08bn. German company Merck KGaA has signed an exclusive licence agreement with Swiss biopharma company Debiopharm for its late-stage oncology ... Merck KGaA will pay Debiopharm 188m upfront

Latest news

Merck and Roche team up for hepatitis C studies

Meanwhile, a range of other new HCV drugs are coming through the pharma industry's pipelines, including Novartis and Debiopharm's DEB025, Boehringer Ingelheim's BI 201335, Bristol-Myers Squibb 's
More Eloxatin settlements for sanofi-aventis

Mayne/Hospira, MN/Par and Actavis have all settled outstanding litigation regarding certain formulations of Eloxatin, currently under licence by S-A and Debiopharm.
Sanofi-aventis settles Eloxatin lawsuits

medicine. S-A, who hold patent rights for the drug along with Swiss-based Debiopharm, did not give any other details regarding the recent settlements, including financial.
Novartis gain rights to hepatitis C drug

The Swiss drugmakers will make an undisclosed upfront payment to Debiopharm Group, an independent biopharmaceuticals company based in Switzerland, with Novartis receiving exclusive worldwide development and marketing rights (excluding Japan).
HCV hope on the horizon

The ciclosporin analogue DEBIO 025 (Debiopharm) is a first-in-class cyclophilin inhibitor that has been generally well tolerated in clinical trials to date and may have potential as an addition

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest Intelligence

Pharma deals during January 2013

Debiopharm. Chugai. Licence. Exclusive worldwide licence to FF 284 in oncology.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Senior Content Editor - Biotechnology: Salary TBC

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Principal Medical Writer: Varies on experience

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Account Management: Competitive Salary Offered

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

PMHub

Add my company

Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

WHITE PAPER: Why do men die younger?: It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials: Here are some useful tips to help get your hands on authentically diverse stock photos....
Virtual congresses: video thrilled the cardio tsar: Chris Ross explores the key learnings from a year of virtual congresses...